Niagen Bioscience, Inc.

Niagen Bioscience, Inc.

NAGENYSE / NASDAQHealthcareSmall cap

$1.84-$0.03 (-1.6%)

Last close · Data as of Nov 20, 2026

Market cap
$278.8M
P/E
16.0x
EV / EBITDA
13.8x
Revenue
$129.4M
Net margin
13.4%
ROCE
16.5%

-72.6% over the last year

Niagen Bioscience, Inc. price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
-26.7%
3M
-41.6%
6M
-50.9%
1Y
-72.6%
5Y
-65.9%

52-week range

Day change -$0.03 (-1.6%) from $1.87 to $1.84 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in NAGE, bought on each weekday since 2021.

News & filings

What Niagen Bioscience filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

StrengthEBITDA grew 71.0% in fiscal 2025, 41.0 points more than revenue.

Concerns (1)

  • The price is 49.3% below its 200-day average, and the 50-day average is below the 200-day.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

Niagen Bioscience, Inc. operates as a bioscience company engages in developing healthy aging products. The company operates through Consumer products; Ingredients; and Pharmaceutical Segments.

Read moreShow less

Niagen Bioscience, Inc. operates as a bioscience company engages in developing healthy aging products. The company operates through Consumer products; Ingredients; and Pharmaceutical Segments. It provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; nicotinamide adenine dinucleotide (NAD+), an essential coenzyme that regulates cellular metabolism; and develops and commercializes proprietary-based ingredient technologies, including food-grade, Niagen, and pharmaceutical-grade Niagen and supplies these ingredients as raw materials to the manufacturers of consumer products. In addition, it commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient under NIAGEN brand name. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, and other internet marketplaces, as well as specialty retailers and authorized healthcare practitioners resellers. The company was formerly known as ChromaDex Corporation and changed its name to Niagen Bioscience, Inc. in March 2025. Niagen Bioscience, Inc. was founded in 1999 and is headquartered in Los Angeles, California.

Sector
Healthcare
Shares outstanding
79.0M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$278.8M
P/E
16.0x
P/B
3.6x
EV / EBITDA
13.8x
EV / Sales
1.7x
P/S
2.2x
52-week high
$7.04
52-week low
$1.84

Profitability

Operating margin
11.0%
Net margin
13.4%
EBITDA margin
12.2%
ROE
22.7%
ROCE
16.5%
ROIC
92.8%
ROA
16.3%
Asset turnover
1.22

Growth

Revenue
$129.4M
Revenue growth, 1Y
29.9%
Revenue CAGR, 3Y
21.6%
Net profit growth, 1Y
103.3%
Free cash flow
$13.2M

Solvency

Current ratio
4.86
Debt / Equity
0.04
Debt / Assets
0.03
CFO / Net profit
0.78
Cash / Market cap
23.2%

Where the revenue went

Of every $100 of FY2025 revenue, $13 was left as net income.

Niagen Bioscience, Inc. income statement flow, FY2025
Niagen Bioscience, Inc. income statement flow, FY2025: flows
FromToAmount
RevenueCost of revenue$46.2M
RevenueGross profit$83.2M
Gross profitResearch and development$6.3M
Gross profitSelling, general and administrative$62.6M
Gross profitOperating income$14.3M
Operating incomePretax income$14.3M
Interest and other incomePretax income$3.9M
Pretax incomeTax and other$810.0k
Pretax incomeNet income$17.4M

Revenue and net profit

Revenue grew 29.9% in FY2025; net profit is the dashed line.

Niagen Bioscience, Inc. revenue and net profit by fiscal year
Niagen Bioscience, Inc. revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$72.0M-$16.5M
FY2023$83.6M-$4.9M
FY2024$99.6M$8.6M
FY2025$129.4M$17.4M

Cash flows

FY2025: $13.5M from operations, $13.2M free after investment (dashed).

Niagen Bioscience, Inc. operating and free cash flow by fiscal year
Niagen Bioscience, Inc. operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022-$15.1M-$15.4M
FY2023$7.1M$7.0M
FY2024$12.1M$11.9M
FY2025$13.5M$13.2M

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$129.4M+29.9%1Y
EBITDA
$15.7M+71.0%1Y
Net profit
$17.4M+103.3%1Y
Cash from operations
$13.5M+11.5%1Y
Free cash flow
$13.2M+10.6%1Y
Revenue CAGR, 3Y
21.6%
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$129.4M$15.7M$17.4M$13.2M22.7%+29.9%+103.3%

Monthly returns

Month-by-month returns of NAGE across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$106.4M
Liabilities$29.9M
Equity$76.5M
Paid-in capital$241.0M
Retained earnings-$164.5M

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; NAGE highlighted.

P/E against peers

NAGE trades at 16.0x earnings against a peer median of -4.9x.

  1. Niagen Bioscience, Inc. (this company)16.0x

Not shown (no positive earnings and no EV / Sales): Eledon Pharmaceuticals, Inc., Anavex Life Sciences Corp.

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
Niagen Bioscience, Inc.NAGEthis company$278.8M16.0x3.6x22.7%13.8x
Alpha Teknova, Inc.TKNO$291.1M-16.9x4.2x-25.1%-30.9x
OraSure Technologies, Inc.OSUR$287.1M-4.2x0.8x-20.2%-1.7x
Quantum-Si incorporatedQSI$278.7M-2.8x1.3x-46.0%-2.8x
Eledon Pharmaceuticals, Inc.ELDN$277.9M-6.1x3.4x-56.3%-3.1x
Entrada Therapeutics, Inc.TRDA$271.7M-1.9x0.9x-47.0%-1.5x
Anavex Life Sciences Corp.AVXL$261.3M-5.6x2.8x-48.9%—
Akebia Therapeutics, Inc.AKBA$260.3M-48.7x8.0x-16.4%5.9x
Fate Therapeutics, Inc.FATE$257.6M-1.9x1.2x-65.8%-2.1x
Peer median—-4.9x2.0x-46.5%-2.1x

Year-to-date ROI

NAGE since 1 January, against earlier years.

Historical volatility

NAGE's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

Niagen Bioscience, Inc. operating margin by fiscal year
Niagen Bioscience, Inc. operating margin by fiscal year
DateOperating margin
FY2022-25.9%
FY2023-6.7%
FY20247.8%
FY202511.0%
LineFY2025
Cost of revenueCost Of Revenue$46.2M
Gross profitGross Profit$83.2M
Operating expensesOperating Expense$68.9M
Research and developmentResearch And Development$6.3M
Total expensesTotal Expenses$115.1M
Pretax incomePretax Income$18.2M

Learn while you research

Academy chapters picked for Niagen Bioscience, Inc. and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Growth Investing30% revenue growth is in the top tier, learn how to value growth.7 min read
  3. 03 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
  4. 04 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  5. 05 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  6. 06 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →